An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I consortium welcomes you to our first newsletter! We are very happy that our project ProCAncer-I on dealing with prostate cancer was funded by the EU and that through its successful...
Βy Prof. Daniele Regge [Chief of the Radiology Unit, Candiolo Cancer Institute, Torino-Italy] and Simone Mazzetti [Candiolo Cancer Institute, Torino-Italy] Prostate cancer is the most frequently diagnosed tumour in Europe with one new cancer detected every...
Βy Prof Kostas Marias [Foundation for Research and Technology - Hellas (FORTH)], Ioannis Karatzanis [Foundation for Research and Technology - Hellas (FORTH)] and Katerina Nikiforaki [Foundation for Research and Technology - Hellas (FORTH)] Anonymization is an...
Βy Nickolas Papanikolaou [Principal Investigator in Oncologic Imaging at the Fundação Champalimaud] Why did you select prostate cancer as the center of your research? What kind of clinical unmet needs will be addressed in ProCancer-I? Prostate cancer is among the most...
By the legal team of ProCAncer-I, The University of Vienna Department of Innovation and Digitalisation in Law (UNIVIE) Given the innovative nature of the technology being developed in the ProCAncer-I project, complex legal questions have arisen concerning the...
By the Radboud UMC Radboudumc is one of the leading centres for prostate cancer imaging worldwide. Within the ProCAncer-I project, two groups of the Department of Imaging of Radboudumc are represented. The Diagnostic Image Analysis Group (DIAG), under the...
By the University of Vienna – Department of Innovation and Digitalisation in Law (UNIVIE) The University of Vienna is the oldest University in the German-speaking world, and the Department of Innovation and Digitalisation in Law is the newest addition to the...
Newsletter #1 Contents
An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging...
Prostate cancer is the second most commonly diagnosed cancer in men. Conventional screening relies on prostate specific antigen (PSA) levels in the blood, which can indicate prostate abnormalities but lacks specificity. Clinical examination and ultrasound also have...
The ProCAncer-I project aims to revolutionize prostate cancer diagnosis and treatment through the power of artificial intelligence and advanced imaging. By creating a large, federated database of prostate MRI scans and clinical data, the project enables the...
ProCAncer-I results | Prof. Daniele Regge on clinical validation In this video, we present the results of the clinical validation of AI models that were developed during the ProCAncer-i Project. Clinical validation is a critical step to ensure that AI tools not only...